By Akinwale Kasali
The National Agency for Food and Drug Administration and Control (NAFDAC) has approved the use of Gardasil vaccine as single dose in the routine immunization against cervical cancer.
In a joint statement by NAFDAC and the National Primary Health Care Development Agency (NPHCDA), Director General of NAFDAC, Prof. Mojisola Adeyeye, said NPHCDA will commence the introduction of the off-label use of quadrivalent Gardasil vaccine as a single dose schedule into the routine immunisation in Nigeria in the last quarter of 2023.
She explained that data from immunogenicity trials, post-hoc analyses of efficacy trials, and post-licensure observational studies among females have demonstrated that a single dose of HPV vaccine was sufficient to elicit an immune response that provides similar protection as a multidose regimen against initial and persistent HPV infection.
According to the World Health Organization (WHO), about 119,000 new cases and 81,000 deaths from cervical cancer occurred in Africa in 2020, accounting for 22.5% of the global burden.
Prof Adeyeye said: “Nigeria, the most populous country in Africa, has one of the highest cervical cancer incidence and mortality rates in the continent, with an estimated 15,000 new cases and 10,000 deaths annually. Several factors contribute to the high disease burden of cervical cancer in Nigeria, such as low awareness, poor screening coverage, limited access to treatment, and high prevalence of human papillomavirus (HPV) infection.
“Human Papillomavirus infection (HPV infection) is caused by a DNA virus belonging to the family Papillomaviridae. The virions are non-enveloped and contain a double-stranded DNA genome. HPV is the most common viral infection of the reproductive tract and causes a range of conditions
in men and women, including pre-cancerous lesions that may progress to cancer.
“The decision to deploy the off-label Gardasil as a single dose schedule is based on the scientific evidence that a single dose of Gardasil vaccine can provide solid protection against cervical cancer caused by human papillomaviruses (HPVs).
“The benefits of the single dose Schedule include; Reducing the cost and logistical challenges of delivering multiple doses, especially in resource-limited settings, Increasing the coverage and equity of HPV vaccination, as more girls and women can access the vaccine, accelerating the elimination of cervical cancer as a public health problem,
“Gardasil is a vaccine that protects against human papillomavirus – HPV -, a common sexually transmitted infection that can cause cervical, vaginal, vulvar, and other cancers.
The vaccine is given two or three doses, depending on the age of the person receiving it.
“At 18 months post-vaccination, the efficacy of a single dose of HPV vaccine against incident persistent high-risk (HPV16/18) infection was 97.5% (95% CI 82–100) for the nonvalent vaccine and 97.5% (95% CI 82–100) for the bivalent vaccine.
“Gardasil has been granted registration approval by the National Agency for Food and Drug Administration and Control (NAFDAC) in exercising its mandate as stipulated by its enabling law, NAFDAC Act CapN1, LFN 2004 and after rigorous regulatory evaluation process for vaccines. The single dose has comparable efficacy and duration of protection as a 2-dose schedule and may offer programme advantages, is more efficientand affordable, and contribute to improved coverage.
 has approved the use of Gardasil vaccine as single dose in the routine immunization against cervical cancer.){kind=link}